Navigation Links
TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients
Date:9/20/2011

CLEVELAND, Sept. 20, 2011 /PRNewswire/ -- TheraVasc (www.theravasc.com) announced the successful completion of a Phase I clinical trial of a drug, TV1001, to diabetic patients. The trial included 12 diabetic patients who each received a single dose of two different oral formulations of TV1001, an enteric coated and a non-enteric coated capsule, to determine safety and blood levels of the drug.  Based on prior studies conducted in animals, the circulating blood levels in all patients were in the range believed to be therapeutic.

"Many of the patients treated in this study have severe chronic wounds for which no effective treatments are available. Based on the safety of the drug we observed in this study and the ability to achieve a therapeutic benefit in animals at the dose tested in this study, this drug offers hope that someday we might have a way of effectively treating these diabetic ulcers," said Dr. Frank Greenway, the Principal Investigator of the Study and Director of the Outpatient Clinic at the Pennington Biomedical Research Center.

Few adverse events were reported during the trials and there was no significant increase in methemoglobin levels, which would have prevented the release of oxygen in the blood, at the dose tested, the most likely adverse event associated with the treatment.  

TheraVasc's previously conducted animal studies using TV1001 showed that when taken chronically, similar blood levels resulted in the generation of new blood vessels in oxygen-deprived limbs, improvement in wound healing, and inhibition of tissue necrosis. The company expects to complete Phase IIa trials in mid-2012 in which the safety of multiple doses of chronically administered TV1001 will be assessed, along with testing for evidence of biological activity.

TheraVasc is initially developing TV1001 as a treatment for diabetic patients with Peripheral Arterial Disease (PAD), a condition affec
'/>"/>

SOURCE TheraVasc Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... China , May 22, 2015  China Nepstar ... "Company"), a leading retail drugstore chain in ... operated stores, today announced the resignation of Mr. ... for personal reasons, effective immediately. Ms. Rebecca Yingnan ... by the Company,s board of directors, effective immediately. Meanwhile, ...
(Date:5/21/2015)... 2015 Research and ... addition of the "Arthroscopy Devices Markets ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of this ... world market for Arthroscopy Devices. The report ... the market for these products. , ,Product ...
(Date:5/21/2015)... NEW YORK , 21. Mai ... (NASDAQ: DPRX ), ein Unternehmen ... sich auf die Entwicklung und Vermarktung ... Forschungszusammenarbeit konzentriert, kündigte heute eine wissenschaftliche ... der Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... Fla., July 5, 2011 MSC Care Management, a ... management solutions to the workers, compensation industry, has launched ... to help relieve the administrative burden for claims adjusters ... a proprietary online tool that allows for faster and ...
... Tourette Syndrome Association, Inc., (TSA) has unveiled a 115-square ... generate awareness and acceptance of all people living with ... "We Have Tourette,s But Tourette,s Doesn,t Have Us" is ... everyday with the symptoms of involuntary sounds and movements ...
Cached Medicine Technology:MSC CareConnect Provides Real-Time, Online Communication and Referral Management to Claims Professionals 2EHE International Showcases The National Tourette Syndrome Association, Inc. with Month-Long Window Display in Rockefeller Center Plaza 2
(Date:5/23/2015)... A live auction will be held to sell ... and other medical facilities around the United States. Various ... surgery, anesthesia, exam and much more. , The live ... 28 starting at 9:00am CDT each day. The equipment is ... Melrose Park, IL 60160. Anyone can participate in the ...
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ... as simple as dragging and dropping footage into the FCPX ... effect. , Including over 80 stunning flares, ProFlare 5K ... this the ultimate bundle for adding prismatic refractions to any ... are movie files designed for Final Cut Pro X, but ...
(Date:5/22/2015)... 2015 The world is at ... are intersecting to create new opportunities for leadership ... speaker at WesternU's 34th annual Commencement Exercises said ... Newsom, a former San Francisco mayor and likely ... the graduation ceremony for WesternU's colleges of Allied ...
(Date:5/22/2015)... The American College of Traditional Chinese Medicine ... will hold a webinar on the updates of the ... Classical Chinese Medicine. , Webinar – First Professional Doctorate ... Dean of Clinical Education, will lead this webinar in ... program. ACTCM is currently developing this degree program based ...
(Date:5/22/2015)... 22, 2015 River Valley Health Partners ... the health system’s Chief Financial Officer (CFO), will be ... served as the company CFO since 2011. , The ... joining the health system as CFO. Wesley will oversee ... while the Board of Trustees conducts a formal search ...
Breaking Medicine News(10 mins):Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2
... ... Options for Taste, Price and Flavor Needs , ... Qufu, China and Erlanger, KY (PRWEB) March 25, 2010 ... high quality Stevia extracts, and WILD Flavors, Inc. ("WILD Flavors"), a global leader in ...
... 25 March 2010 - One of the most common complaints ... performance. This decline has been linked to an inability to ... distracting information, the brain should act to suppress its responses ... adults there is in fact an increase in brain activity ...
... recent study confirms that the standard hepatitis C (HCV) ... in urban minority patients treated in an ordinary clinical ... Results of this study appear in the April ... Wiley-Blackwell on behalf of the American Association for the ...
... ... new user-friendly Web site to increase convenience and services for patients , ... Chicago, IL (PRWEB) March 25, 2010 -- Grove ... Grove, Bolingbrook, Lombard or Wheaton dentist , announces the recent launch of its new ...
... safety for the thrill of a ,lucky, escape, experts say ... are the time in life when people are most likely ... and drugs, and a new study suggests they do these ... teenagers take risks is not a problem with foreseeing the ...
... children,s health and well-being, experts say , THURSDAY, March ... the nation,s workforce unemployed, the emotional impact of a ... the psychological fallout can be equally tough for their ... one parent is jobless potentially face a range of ...
Cached Medicine News:Health News:Sunwin International & WILD Flavors Receive GRAS Letters of No Objection from FDA Validating Safety of Multiple Sunwin Stevia Extracts 2Health News:Sunwin International & WILD Flavors Receive GRAS Letters of No Objection from FDA Validating Safety of Multiple Sunwin Stevia Extracts 3Health News:Memory decline linked to an inability to ignore distractions 2Health News:Hepatitis C treatment less effective in urban minority patients 2Health News:Hepatitis C treatment less effective in urban minority patients 3Health News:Leading Downers Grove Dentist Team at Grove Dental Launches New Web Site 2Health News:Teens Take Risks Just for Kicks 2Health News:Parents Aren't Only Ones Who Feel Stress of Unemployment 2Health News:Parents Aren't Only Ones Who Feel Stress of Unemployment 3
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
... The Wampole PreVue B. Burgdorferi Antibody ... membrane assay for the qualitative presumptive (first ... to B. burgdorferi in human serum or ... use and relative accuracy make the Wampole ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: